Form 4 for HRMY Harmony Biosciences Holdings, Inc.
Accepted 2021-10-20 00:00:00 ET · period of report 2021-10-19 · accession 0001104659-21-128203 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-10-20 | 2021-10-19 | HRMY | Dayno Jeffrey M. | Chief Medical Off | M - OptEx | $8.22 | +18.2K | 4,101 | New | +$149.6K |
| DM | 2021-10-20 | 2021-10-19 | HRMY | Dayno Jeffrey M. | Chief Medical Off | S - Sale+OE | $43.27 | -18.2K | 0 | -100% | -$787.6K |
| DM | 2021-10-20 | 2021-10-19 | HRMY | Dayno Jeffrey M. | Chief Medical Off | M - OptEx | $0.00 | -18.2K | 53.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-10-19 | M | A | 14,099 | $8.22 | 14,099 | D | — | — | |
| 2 | Common | Common Stock | 2021-10-19 | S | D | 4,101 | $43.77 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.99. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2021-10-19 | M | A | 4,101 | $8.22 | 4,101 | D | — | — | |
| 4 | Common | Common Stock | 2021-10-19 | S | D | 14,099 | $43.13 | 0 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.65 to $43.63. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Stock Option | 2021-10-19 | M | D | 14,099 | $0.00 | 57,570 | D | $8.22 · — to 2027-11-13 | 14,099 Common Stock | (F4) The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. |
| 6 | Derivative | Stock Option | 2021-10-19 | M | D | 4,101 | $0.00 | 53,469 | D | $8.22 · — to 2027-11-13 | 4,101 Common Stock | (F4) The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. |